St. Jude wins CE mark for hypertension treatment device

The race to launch new cardiac rhythm management devices continues. This time, St. Jude Medical ($STJ) is rolling out its EnligHTN renal denervation system in Europe, following CE mark approval. The device uses a number of electrodes and radiofrequency energy to selectively sear, or disable, renal nerves traveling from the arteries to the kidneys, with the goal of treating hypertension for patients who haven't responded to other, more traditional treatments, Bloomberg explains. Competition will be, well, fierce, the article reminds us, with rivals in the space including Medtronic ($MDT), Covidien ($COV) and Vessix Vascular. Story

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.